Intangible Assets (Narrative) (Details)	12 Months Ended				12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2011 Eli Lilly and Company [Member] USD ($)	Dec. 31, 2011 Auralis Contract Rights [Member]	Dec. 31, 2011 Auralis Product Rights [Member]	Dec. 31, 2011 IPR&D Asset And Auralis Contract Rights [Member] USD ($)	Dec. 31, 2011 IPR&D Asset And Auralis Contract Rights [Member] GBP (£)	Dec. 31, 2011 Plenadren Product Rights [Member]	Dec. 31, 2011 Year One [Member]	Dec. 31, 2011 Year Two [Member]	Dec. 31, 2011 Year Three [Member]
Finite-Lived Intangible Assets [Line Items]
Additional aggregate purchase price of acquired entity				$ 51,100,000
Maximum sales used to determine additional contingent consideration payable	65,000,000
Useful life of acquired intangible assets, years					12	10	10	10	10
Impairment charges							8,500,000	5,400,000
sNDA approval, number of patients data was collected	260
Exclusivity period of vancomycin capsules in years	three
Royalties on net sales of Vancocin, Percentage										10.00%	10.00%	16.00%
Amortization expense	$ 31,035,000	$ 29,357,000	$ 28,183,000